Open access
Open access
Powered by Google Translator Translator

5-year follow up of a RCT: Ruxolitinib versus best available therapy in inadequately controlled polycythemia vera without splenomegaly.

23 Jun, 2022 | 09:55h | UTC

Ruxolitinib versus best available therapy in inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): 5-year follow up of a randomised, phase 3b study – The Lancet Haematology (link to abstract – $ for full-text)

Original Study: Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b study – The Lancet Oncology (link to abstract – $ for full-text)

 

Commentary on Twitter

 


Stay Updated in Your Specialty

No spam, just news.